Multiple System Atrophy

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Second Edition

Volumn , Issue , 2011, Pages 242-252

  Holton, Janice L ^a   Lees, Andrew J ^a   Revesz, Tamas ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

synuclein; synucleinopathy; Glial cytoplasmic inclusion; Multiple system atrophy; Neuronal cytoplasmic inclusion; Neuropathology; Olivopontocerebellar atrophy; Review; Striatonigral degeneration

Indexed keywords

EID: 84864829369     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341256.ch24     Document Type: Chapter

References (84)

1. Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
2. Dejerine J, Thomas AA. L'atrophie olivo-ponto-cérébelleuse. Nouv Iconogr Salpêtr 1900; 13: 330-370.
3. Adams RD, van Bogaert L, van der Eeken H. Dégénérescences nigro-striées et cérébello-nigro-striées. Psychiat Neurol 1961; 142: 219-259.
4. Shy GM, Drager GA. A neurologic syndrome associated with orthostatic hypotension. Arch Neurol 1960; 2: 511-527.
5. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969; 32: 28-34.
6. Gilman S, Little R, Johanns J et al. Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000; 55: 527-532.
7. Klockgether T, Schroth G, Diener HC, Dichgans J. Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatry 1990; 53: 297-305.
8. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94: 79-100.
9. Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord 2008; 23: 294-296.
10. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49: 1284-1288.
11. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-1775.
12. Wüllner U, Schmitz-Hübsch T, Abele M, Antony G, Bauer P, Eggert K. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J Neural Transm 2007; 114: 1161-1165.
13. Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998; 57: 1099-1111.
14. Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178.
15. Hara K, Momose Y, Tokiguchi S et al. Multiplex families with multiple system atrophy. Arch Neurol 2007; 64: 545-551.
16. Wüllner U, Schmitt I, Kammal M, Kretzschmar HA, Neumann M. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 2009; 80: 449-450.
17. Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, Sasaki H. Heredity in multiple system atrophy. J Neurol Sci 2006; 240: 107-110.
18. Ozawa T, Takano H, Onodera O et al. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett 1999; 270: 110-112.
19. Singleton AB, Farrer M, Johnson J et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
20. Lincoln SJ, Ross OA, Milkovic NM et al. Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. Parkinsonism Relat Disord 2007; 13: 340-342.
21. Ozawa T, Okuizumi K, Ikeuchi T, Wakabayashi K, Takahashi H, Tsuji S. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol (Berl) 2001; 102: 188-190.
22. Scholz SW, Houlden H, Schulte C et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009; 65: 610-614.
23. Al-Chalabi A, Dürr A, Wood NW et al. Genetic variants of the alphasynuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009; 4: 7114.
24. Ross OA, Vilariño-Güell C, Wszolek ZK, Farrer MJ, Dickson DW. SNCA variants are associated with increased risk of multiple system atrophy. Ann Neuro 2010; 67: 414-415.
25. Yun JY, Lee WW, Lee JY, Kim HJ, Park SS, Jeon BS. SNCA variants and multiple system atrophy. Ann Neurol 2010; 67: 554-555.
26. Ince PG, Clark B, Holton J, Revesz T, Wharton SB. Disorders of movement and system degenerations. In: Ellison DW, Louis DN, Love S (eds) Greenfield's Neuropathology, 8th edn. London: Arnold, 2007.
27. Ozelius LJ, Foroud T, May S et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord 2007; 22: 546-549.
28. Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 2009; 15: 300-306.
29. Wenning GK, Ben SY, Magalhäes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117: 835-845.
30. Wenning GK, Stefanova N. Recent developments in multiple system atrophy. J Neurol 2009; 256: 1791-1808.
31. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994; 151: 1336-1341.
32. Robbins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD. Cognitive performance in multiple system atrophy. Brain 1992; 115: 271-291.
33. Seppi K, Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 2010; 20: 29-55.
34. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RS. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism. Diagnostic implications of the D2 receptor status. Brain 1993; 116: 853-867.
35. Schulz JB, Klockgether T, Petersen D et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-1056.
36. Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009; 24: 949-964.
37. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 2009; 24: 1650-1655.
38. Stocchi F, Carbone A, Inghilleri M et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997; 62: 507-511.
39. Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58: 618-621.
40. Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. "Minimal change" multiple system atrophy. Mov Disord 1994; 9: 161-166.
41. Wakabayashi K, Ikeuchi T, Ishikawa A, Takahashi H. Multiple system atrophy with severe involvement of the motor cortical areas and cerebral white matter. J Neurol Sci 1998; 156: 114-117.
42. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 2007; 27: 484-493.
43. Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007; 33: 615-620.
44. Ozawa T, Paviour D, Quinn NP et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004; 127: 2657-2671.
45. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord Suppl 2005; 12: S29-S36.
46. Ozawa T, Tada M, Kakita A et al. The phenotype spectrum of Japanese multiple system atrophy. J Neurol Neurosurg Psychiatry 2010; 81: 1253-1255.
47. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994; 117: 235-243.
48. Ozawa T. Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum. Acta Neuropathol (Berl) 2007; 114: 201-211.
49. Song YJ, Halliday GM, Holton JL et al. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol 2009; 68: 1073-1083.
50. Ishizawa K, Komori T, Arai N, Mizutani T, Hirose T. Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: A quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system). Neuropathology 2008; 28: 249-257.
51. Borit A, Rubinstein LJ, Urich H. The striatonigral degenerations. Putaminal pigments and nosology. Brain 1975; 98: 101-112.
52. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992; 32 Suppl: S94-S100.
53. Matsuo A, Akiguchi I, Lee GC, McGeer EG, McGeer PL, Kimura J. Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 1998; 153: 735-744.
54. Kato S, Nakamura H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol (Berl) 1990; 79: 584-594.
55. Nakazato Y, Yamazaki H, Hirato J, Ishida Y, Yamaguchi H. Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. J Neuropathol Exp Neurol 1990; 49: 521-530.
56. Papp MI, Lantos PL. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 1992; 107: 172-182.
57. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998; 251: 205-208.
58. Inoue M, Yagishita S, Ryo M, Hasegawa K, Amano N, Matsushita M. The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems. Acta Neuropathol (Berl) 1997; 93: 585-591.
59. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998; 249: 180-182.
60. Wakabayashi K, Takahashi H. Cellular pathology in multiple system atrophy. Neuropathology 2006; 26: 338-345.
61. Cairns NJ, Atkinson PF, Hanger DP, Anderton BH, Daniel SE, Lantos PL. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neurosci Lett 1997; 230: 49-52.
62. Kuusisto E, Kauppinen T, Alafuzoff I. Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 2008; 34: 169-180.
63. Arima K, Murayama S, Mukoyama M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Acta Neuropathol (Berl) 1992; 83: 453-460.
64. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
65. Campbell BC, McLean CA, Culvenor JG et al. The solubility of alphasynuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 2001; 76: 87-96.
66. Dickson DW, Liu W, Hardy J et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999; 155: 1241-1251.
67. Fujiwara H, Hasegawa M, Dohmae N et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-164.
68. Duda JE, Giasson BI, Chen Q et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000; 157: 1439-1445.
69. Duda JE, Giasson BI, Gur TL et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000; 59: 830-841.
70. Giasson BI, Duda JE, Murray IV et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290: 985-989.
71. Cookson MR. Alpha-synuclein and neuronal cell death. Mol Neurodegener 2009; 4: 9-23.
72. Pountney DL, Lowe R, Quilty M, Vickers JC, Voelcker NH, Gai WP. Annular alpha-synuclein species from purified multiple system atrophy inclusions. J Neurochem 2004; 90: 502-512.
73. Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease-a retrospective comparison. Acta Neurol Scand 1995; 91: 98-102.
74. Lipp A, Sandroni P, Ahlskog JE et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009; 66: 742-750.
75. Silveira-Moriyama L, González AM, O'Sullivan SS et al. Concomitant progressive supranuclear palsy and multiple system atrophy: more than a simple twist of fate? Neurosci Lett 2009; 467: 208-211.
76. Fujishiro H, Ahn TB, Frigerio R et al. Glial cytoplasmic inclusions in neurologically normal elderly: prodromal multiple system atrophy? Acta Neuropathol 2008; 116: 269-275.
77. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. Trends Neurosci 2005; 28: 501-506.
78. Ubhi K, Lee PH, Adame A et al. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. J Neurosci Res 2009; 87: 2728-2739.
79. Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM. Alphasynuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res 2000; 62: 9-14.
80. Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm 2005; 112: 1613-1624.
81. Song YJ, Lundvig DM, Huang Y et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 2007; 171: 1291-1303.
82. Huang Y, Song YJ, Murphy K et al. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol 2008; 116: 639-646.
83. Qing H, Zhang Y, Deng Y, McGeer EG, McGeer PL. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem Biophys Res Commun 2009; 390: 1229-1234.
84. Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 2007; 22: 2196-2203.